These findings suggest that TRPC3 and TRPC6 are unlikely to be implicated in liver dysfunction and fibrosis in NAFLD mouse models.328 No effective therapy is available for NAFLD, and its exact pathogenesis remains to be elucidated. This evidence concerns the gene TRPC6 and metabolic dysfunction-associated steatotic liver disease.